Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). | MicrobiomeTrials← Back to trialsNCT06431776
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-10-22Est. Completion: 2027-06
Enrollment target: 5 participants Locations- Ludwig Maximilians Universität München - Dr. von Haunersches Kinderspital - Kinderklinik und Kinderpoliklinik, München, Germany
Other microbiome trials you might be interested in
Autoimmune Pulmonary Alveolar Proteinosis
Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disorder in which a material called surfactant builds up in t…
Los Angeles, United States
Pulmonary Alveolar Proteinosis
The major goal of Part A of this study is to establish a National PAP Registry to help make reliable new research tests …
Cincinnati, United StatesEst. completion Dec 2030